Literature DB >> 11052322

Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.

L M Lichtenberger1, J J Romero, G W Gibson, M A Blank.   

Abstract

Bisphosphonates are a family of chemically related zwitterionic molecules that are used clinically to retard bone resorption in individuals with osteoporosis and associated skeletal diseases. Inflammation and ulceration of the upper gastrointestinal tract by a mechanism that relates to a topical irritant action is associated with the consumption of some bisphosphonates. In the present study, we investigated the effects of three bisphosphonate molecules, pamidronate, alendronate, and risedronate on the surface hydrophobicity and phosphatidylcholine (PC) concentration of the antral mucosa. We also examined how these surface changes related to mucosal injury in an established rat model, in which the test compounds were administered in combination with indomethacin. We initially determined that a combination of pamidronate (300 mg/kg) and indomethacin (40 mg/kg) induced a significant reduction in mucosal surface hydrophobicity and macroscopic lesion formation by 15 min and mucosal PC concentration by 30 min, with the magnitude of these changes increasing over the 4-hr study period. An equivalent dose of alendronate or risedronate in combination with indomethacin produced modest or no macroscopic injury, respectively, to the antral mucosa over the 4-hr study, although the bisphosphonates clearly induced surface injury and some glandular necrosis when examined at the light microscopic level. These bisphosphonates also induced modest decreases in antral surface hydrophobicity and mucosal PC concentration that appeared to be related to their injurious potential. In conclusion, the variable toxicity of bisphosphonates to the antral mucosa appears to be associated with their ability to compromise the surface hydrophobic phospholipid barrier of the tissue, with pamidronate > > > alendronate > risedronate. This bisphosphonate effect on the surface barrier may trigger the development of mucosal injury and possible ulceration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052322     DOI: 10.1023/a:1005574009856

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  THIN-LAYER CHROMATOGRAPHY OF PHOSPHOLIPIDS USING SILICA GEL WITHOUT CALCIUM SULFATE BINDER.

Authors:  V P SKIPSKI; R F PETERSON; J SANDERS; M BARCLAY
Journal:  J Lipid Res       Date:  1963-04       Impact factor: 5.922

2.  Multiple ulcerative esophagitis caused by alendronate.

Authors:  G Maconi; G Bianchi Porro
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

3.  Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach.

Authors:  B A Hills; B D Butler; L M Lichtenberger
Journal:  Am J Physiol       Date:  1983-05

4.  Nonclinical model for assessing gastric effects of bisphosphonates.

Authors:  M A Blank; B L Ems; G W Gibson; W R Myers; S K Berman; R J Phipps; P N Smith
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

5.  Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects.

Authors:  B S Anand; J J Romero; S K Sanduja; L M Lichtenberger
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

6.  Gastric mucosal hydrophobicity in duodenal ulceration: role of Helicobacter pylori infection density and mucus lipids.

Authors:  M Asante; H Ahmed; P Patel; T Davis; C Finlayson; M Mendall; T Northfield
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

7.  Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.

Authors:  D Y Graham; H M Malaty; R Goodgame
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

8.  Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication.

Authors:  P M Goggin; J M Marrero; R T Spychal; P A Jackson; C M Corbishley; T C Northfield
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

Review 9.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Effect of ammonium ion on the hydrophobic and barrier properties of the gastric mucus gel layer: implications on the role of ammonium in H. pylori-induced gastritis.

Authors:  L M Lichtenberger; J J Romero
Journal:  J Gastroenterol Hepatol       Date:  1994       Impact factor: 4.029

View more
  24 in total

1.  Protective effect of melatonin and omeprazole against alendronat-induced gastric damage.

Authors:  Goksel Sener; Figen Onuk Goren; Nefise B Ulusoy; Yasemin Ersoy; Serap Arbak; Gül Ayanoglu Dülger
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.

Authors:  Y-L Peng; H-Y Hu; J-C Luo; M-C Hou; H-C Lin; F-Y Lee
Journal:  Osteoporos Int       Date:  2014-02-25       Impact factor: 4.507

3.  Chemical injury caused by acute alendronic acid aspiration.

Authors:  Zoe Victoria Ottaway; Cara Hammond; Simon Merritt
Journal:  BMJ Case Rep       Date:  2014-04-30

4.  Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.

Authors:  Beate Aurich Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2005-08-31       Impact factor: 4.507

5.  Low concentration amino-bisphosphonates stimulate human keratinocyte proliferation and in vitro wound healing.

Authors:  Filippo Renò; Mario Migliario; Manuela Rizzi; Marco Invernizzi; Carlo Cisari; Mario Cannas
Journal:  Int Wound J       Date:  2011-12-19       Impact factor: 3.315

6.  Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.

Authors:  A B R Thomson; S Appleman; M Keelan; J L Wallace
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

7.  Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy.

Authors:  Kazumasa Miyake; Masanori Kusunoki; Yoko Shinji; Tomotaka Shindo; Tetsuro Kawagoe; Seiji Futagami; Katya Gudis; Taku Tsukui; Atsushi Nakajima; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

8.  A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.

Authors:  Toru Yoshioka; Nobukazu Okimoto; Ken Okamoto; Akinori Sakai
Journal:  J Bone Miner Metab       Date:  2012-10-19       Impact factor: 2.626

9.  Candida-associated gastric ulcer relapsing in a different position with a different appearance.

Authors:  Kenji Sasaki
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

10.  Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.

Authors:  Richard Derman; Joseph D Kohles; Ann Babbitt
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.